Recent Articles from Business Wire

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Celsius Holdings, Inc. (NASDAQ: CELH) between February 21, 2025 and June 3, 2026. Celsius describes itself as a company that “develops, processes, manufactures, markets, sells, and distributes products including energy drinks.”

Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) in Madrid, Spain.

Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy.

Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today pivotal results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005). Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below). No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable. These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026. Hims describes itself as a company that “operates a health and wellness platform that connects consumers to licensed healthcare professionals.”

Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in the second-line (2L) setting, confirmed and unconfirmed objective response rates (ORRs) were 75% and 67%, respectively, with an ORR of 81% observed among 1L patients with left-sided tumors. With longer follow-up, most of the previously unconfirmed objective responses were subsequently confirmed, reinforcing the consistency of the clinical activity observed across treatment settings. The updated analyses reinforce the depth and durability of responses observed in both 1L and 2L treatment settings and support the ongoing global Phase 3 development program. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2026, held in Madrid, Spain.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery (neoadjuvant) in patients with solid tumors. The results were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center, in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. Xencor also reported additional follow-up data supporting selection of 400 mcg/kg as the intravenous proposed recommended Phase 3 dose and outlined plans for potential registration-enabling development by the end of 2027.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced promising preliminary clinical data from the ongoing Phase 1 monotherapy portion of its Phase 1/2 PROSPER trial evaluating FMC-376, a KRAS G12C ON+OFF inhibitor, in patients with advanced KRAS G12C-mutant solid tumors, focused on non-small cell lung cancer (NSCLC). The findings were presented during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in CCC Intelligent Solutions Holdings Inc. (“CCC” or “the Company”) (NASDAQ: CCC) for potential breaches of fiduciary duty on the part of its directors and management.

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of common stock of Papa John’s International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026. Papa Johns describes itself as a “global chain pizza company that both operates and franchises restaurants in North America and various international markets.”

Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today in an oral presentation at IDWeek 2026 in Washington, D.C.1

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of SoundThinking, Inc. (NASDAQ: SSTI) to Transom Capital Group for $8.00 per share in cash, and one non-transferable contingent value right worth up to $3.00 per share.

Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment with IMFINZI plus platinum chemotherapy (investigator’s choice of carboplatin or cisplatin) and etoposide.

Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had refused cisplatin-based chemotherapy. Patients in the comparator arm had a radical cystectomy (surgery to remove the bladder) with or without approved adjuvant treatment.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Harte Hanks, Inc. (NASDAQ: HHS) to Star Equity Holdings, Inc. Under the terms of the proposed transaction, Harte Hanks shareholders may elect to receive either (1) $5.00 in cash for each Harte Hanks share, or (2) 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for each Harte Hanks share.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of GoPro, Inc. (NASDAQ: GPRO) to Starman Optical, Inc. for $1.14 per share, subject to potential adjustment based on GoPro’s net working capital at closing.

New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical Trials Group at the European Society for Medical Oncology (ESMO) Congress 2026 will show that adding Bayer’s androgen receptor inhibitor (ARi), NUBEQA® (darolutamide), to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy (RT), improves metastasis-free survival based on conventional imaging (MFS-CI) in prostate cancer patients with high risk of recurrence compared to placebo. These data will be presented at Presidential Symposium I at the ESMO Congress 2026 (LBA4, Saturday, October 24, at 16:30 CEST/10:30 am ET).

Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla.

Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutation, an area with substantial unmet medical need.

Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise.

CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation Factor-15 (GDF-15) blockade with visugromab substantially enhanced the anti-tumor activity of the PD‑1 inhibitor nivolumab in the neoadjuvant treatment of patients with newly diagnosed, checkpoint-inhibitor-naïve muscle-invasive bladder cancer (MIBC). Visugromab is a humanized monoclonal antibody designed to neutralize the tumor-derived cytokine GDF-15, a key mediator of immune suppression and resistance to anti-PD-(L)1 therapies.

Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), an owner and operator of U.S. grocery-anchored real estate, announced today that it has obtained an interim order (the “Interim Order”) of the Ontario Superior Court of Justice (Commercial List) (the “Court”) in connection with the proposed acquisition by EP/BRX Holdings LLC (the “Purchaser”), a joint venture between an affiliate of Brixmor Property Group Inc. and affiliates of Everview Partners, L.P., of all of the REIT’s issued and outstanding units pursuant to the terms and conditions of an arrangement agreement (the “Arrangement Agreement”) among the REIT, the Purchaser and 1001700324 Ontario Inc. dated September 27, 2026 (the “Arrangement”). The Arrangement was previously announced by the REIT on September 28, 2026.

Genesis Healthcare, Inc. (“Genesis”) today announced that its chapter 11 plan became effective, following the closing of the sale of substantially all of its operating assets to 101 W. State Street, LLC (“West State Street”) on October 14, 2026.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NVE Corporation (NASDAQ: NVEC) resulting from allegations that NVE Corporation may have issued materially misleading business information to the investing public.

US Metro Bancorp (OTCQX: USMT): US Metro Bancorp (“Bancorp”) is a bank holding company, with a single subsidiary, US Metro Bank (“Bank”). On a consolidated basis, Bancorp earned $3.1 million in the third quarter of 2026, compared to $3.5 million in the second quarter of 2026. For the nine months ending September 30, 2026, the consolidated Bancorp earned $9.9 million compared to $8.0 million for the nine months ending September 30, 2025. On a year-to-date basis, Bancorp recorded an annualized return on average assets (“ROAA”) of 0.80% and an annualized return on average equity (“ROAE”) of 11.32%. With 16,791,500 shares outstanding, earnings per share (“EPS”) for the third quarter of 2026 was $0.19 compared to $0.21 in the second quarter of 2026. For the nine months ending September 30, 2026, EPS was $0.59 compared to $0.48 for the nine months ending September 30, 2025. On September 30, 2026, Bancorp’s book value per share was $7.06 compared to $6.62 a year earlier.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.

Hawaiian Electric Industries, Inc. (HEI) (NYSE - HE) will announce its third quarter 2026 financial results on Friday, November 6 and conduct a webcast and conference call to discuss the results at 11:30 a.m. Hawaii time (4:30 p.m. Eastern time).

Principal Real Estate Income Fund (the “Fund”), which is traded on the New York Stock Exchange under the symbol “PGZ,” announced Marc Peterson will retire from Principal Real Estate Investors, LLC (“PrinREI”), the dedicated real estate investment team of Principal Asset Management®, on October 23, 2026, and will no longer serve as a portfolio manager of the Fund at that time. Kelly Rush, CIO of global real estate securities, will remain as co-portfolio manager of the Fund and, effective October 23, 2026, Laura Rank, managing director and portfolio manager, and Jason Haigh, portfolio manager, will serve as co-portfolio managers. There will be no changes to the Fund’s investment objectives or investment policies in connection with Peterson’s retirement.

KBRA assigns a long-term rating of BBB- to the Board of Education of the City of Chicago Unlimited Tax General Obligation Bonds (Dedicated Revenues), Series 2026A. KBRA additionally affirms the long-term ratings of BBB- for the District's Unlimited Tax General Obligation Bonds (Dedicated Revenues) without special revenue legal opinions and BBB for the District's Unlimited Tax General Obligation Bonds (Dedicated Revenues) with special revenue legal opinions. The rating Outlook remains Negative.

The recent civil unrest witnessed across France has highlighted the need for Strikes, Riots and Civil Commotion (SRCC) coverage to close the insurance gap from these kinds of events, according to a new AM Best commentary.

Vital Farms (Nasdaq: VITL) announced today the pilot launch of Vital Farms Free-Range eggs, which are expected to arrive in select Target retail stores across the South and Southeast beginning this week.

Nu Holdings Ltd. (NYSE: NU) (“Nu” or the “Company”), one of the world’s largest digital banking platforms, announced that Eric Young, its Chief Technology Officer, has decided to resign to pursue a new professional opportunity. Mr. Young is expected to remain with the Company until November 12, 2026 to support an orderly transition.

KBRA assigns preliminary ratings to three classes of notes from US Signal Issuer LLC and US Signal Co-Issuer LLC Series 2026-1 and Series 2026-2 (together, Series 2026-1/2), a colocation data center ABS transaction. The transaction represents the first ABS issuance issued by US Signal Issuer LLC and US Signal Co-Issuer LLC. All series share in the same collateral pool.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of investors who sold shares of Class A common stock of Skechers U.S.A., Inc. (formerly trading on NYSE: SKX) from April 24, 2025 through the closing of the take-private acquisition of Sketchers by 3G Capital Partners L.P. and its affiliates on September 12, 2025 (the "Class Period"). Skechers is a company that designs and markets footwear, apparel, and accessories in regional offices and showrooms globally.

Myers Industries, Inc. (NYSE: MYE) today announced that its Board of Directors has approved a quarterly cash dividend of $0.135 per share, payable on January 6, 2027, to shareholders of record as of December 4, 2026.

Independence in West Sacramento, a new gated community of 208 townhome-style rental homes developed by Lewis Apartments, will officially open its leasing office and model homes to the public on Saturday, October 24. The leasing office and models will be open daily from 9 a.m. to 6 p.m.

Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab.

AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of patients of Quest Diagnostics, a New Jersey-based diagnostic testing company.

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ServiceTitan, Inc. (NASDAQ: TTAN).

Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today declared its quarterly cash distribution for the third quarter 2026 of $1.14 per common limited partner unit, or $4.56 per common limited partner unit on an annualized basis. The third quarter 2026 cash distribution is payable on November 10, 2026, to unitholders of record on November 3, 2026.

AM Best has affirmed the Financial Strength Rating (FSR) of B++ (Good) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “bbb” (Good) of Redbridge Insurance Company Limited (RICL) (St. James, Barbados) and Redbridge Insurance Company (RIC) (Puerto Rico). The outlook of the FSR is stable while the outlooks for the Long-Term ICRs remain positive.

FICO (NYSE: FICO), global analytics software leader, today announced that it will hold its wholesale mortgage price for the FICO® Score through its tri-merge resellers at $10 for lenders and brokers enrolled in its Preferred Program. The $10 price is for a bundle of both the Classic FICO® Score, the credit score that has served as the industry standard for mortgage lending for nearly three decades, and the FICO® Score 10T, FICO’s modern credit score and the most predictive credit score available to the mortgage industry.

NIKE, Inc. (NYSE: NKE) plans to host an Investor Day on November 16–17, 2026. Due to limited capacity, in-person attendance is by invitation only. The main stage presentations on Tuesday, November 17, 2026, will be webcast live beginning at approximately 8:30 a.m. PT and are expected to conclude at approximately 12:00 p.m. PT at https://investors.nike.com/. A replay of the webcast and related materials will be available at the same location following the event.

Surf Air Mobility Inc. (NYSE: SRFM), a leading air mobility platform, today announced that it will release its third quarter 2026 financial results after market close on Thursday, November 5, 2026, and will host a webcast at 5:00 pm ET the same day.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or “the Company”) (NASDAQ: ERAS) for violations of the securities laws.

River City Bank (Nasdaq: RCBC) ("the Bank") reported net income of $30.6 million or $2.16 per share for the quarter ended September 30, 2026, which compares to $19.7 million, or $1.36 per share, for the same period in 2025. Net income was $68.2 million or $4.75 per share for the nine months ended September 30, 2026, which compares to $47.4 million, or $3.24 per share, for the nine months ended September 30, 2025. The Bank’s earnings for the quarter ended September 30, 2026 resulted in a 21.06% return on average equity and a 1.92% return on average assets. The Bank’s book value per share rose 14% to $42.32 as of September 30, 2026 from $37.04 per share as of September 30, 2025.

AMTD Digital Inc. (“AMTD Digital” or the “Company”, NYSE: HKD), a NYSE listed company and also a comprehensive digital solutions and global hospitality and VIP services platform headquartered in France, announces its unaudited financial results for the six months ended April 30, 2026.

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced the launch of Chain Reaction, a global supply chain decarbonization program designed to help supply partners cut carbon emissions, optimize factory operations and unlock shared business growth. The initiative marks an expansion of Logitech’s climate strategy, providing direct operational support to help suppliers build their own decarbonization roadmaps while advancing Logitech’s science-based target to halve its Scope 3 greenhouse gas (GHG) emissions by 2030.

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time.

The Board of Directors of Peoples Financial Services Corp. (“Peoples”) (NASDAQ: PFIS) declared a fourth quarter cash dividend of $0.6250 per share. The dividend is payable December 15, 2026 to shareholders of record November 30, 2026.

Stem, Inc. (NYSE: STEM), a global leader in AI-enabled clean energy software and services, today announced that on October 19, 2026, it had notified the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual (the “Manual”), which requires a listed company’s average global market capitalization over a consecutive 30 trading-day period to be not less than $50 million and, at the same time, its stockholders’ equity to be not less than $50 million. On October 20, 2026, the Company received a non-compliance letter from the NYSE confirming that the Company is not in compliance with the requirement of Section 802.01B of the Manual (the “NYSE Letter”).

Salesforce (NYSE: CRM), the #1 AI CRM, today announced it has granted equity awards under its 2014 Inducement Equity Incentive Plan (the "Plan") to new employees who joined Salesforce in connection with the acquisition of m3ter and Fin. The Plan was adopted by the Salesforce Board of Directors in July 2014, in accordance with New York Stock Exchange Rule 303A.08.

GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, and the Children’s Tumor Foundation (CTF), NF’s global drug discovery engine focused on neurofibromatosis and schwannomatosis (collectively known as NF), today announced a partnership to advance GondolaBio’s preclinical neurofibromatosis type 1 (NF1) program.

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on Monday, November 9, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Shares of Beneficial Interest — ticker symbol ELME —of Elme Communities (the “Company”) from the NYSE. Trading in the Company’s Shares of Beneficial Interest will be suspended immediately.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Roku, Inc. (“Roku” or “the Company”) (NASDAQ: ROKU) for potential breaches of fiduciary duty on the part of its directors and management.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Caesars Entertainment, Inc. (“Caesars” or “the Company”) (NASDAQ: CZR) for potential breaches of fiduciary duty on the part of its directors and management.

Wolters Kluwer Tax & Accounting today announced the launch of agentic tax return preparation in CCH Axcess™ Tax, further advancing CCH Axcess as the agentic platform for tax and accounting. Built into the cloud-native platform where firms already manage their tax work, agentic tax preparation helps firms reduce repetitive preparation work, increase capacity, and give tax professionals a stronger starting point for review.

Helix Innovations LLC, an operating company of Altria Group, Inc. (Altria) (NYSE: MO), today announced the winners of on!® nicotine pouches’ inaugural on!vitational, held October 16 and 17 at TGL’s SoFi Center in Palm Beach Gardens, Florida. The two-day golf and entertainment experience brought together eight teams of current and former professional athletes, golf personalities, entertainers and adult nicotine consumers age 25+ for a competition that combined golf, technology and entertainment.

The Federal Home Loan Bank of Chicago (FHLBank Chicago) today announced its preliminary and unaudited financial results for the third quarter of 2026.

Elucid Bioimaging Inc. (“Elucid”) today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products.

Liquid Strategies announced the launch of the Overlay Shares Nasdaq 100 Income ETF (OVQ), an actively managed ETF that combines Nasdaq-100 equity exposure with a put-spread options strategy designed to seek to generate income. This is the latest addition to Liquid Strategies’ longstanding experience managing option overlay strategies across the Overlay Shares ETF suite since 2019.

Infinity (Infinity Artificial Intelligence Institute), an automated AI research company building the software layer that makes any AI chip inference-ready, today announced two key hires to its engineering team. Aditya Om, a former senior software engineer at Meta Superintelligence Labs (MSL), joins Infinity as Staff Inference Optimization Engineer, and Elliot Arledge, whose CUDA and LLM coding courses have taught skills to more than two million people, joins as Member of Technical Staff.

PennyMac Mortgage Investment Trust (NYSE: PMT) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 6:30 pm. Eastern Time from the originally scheduled 6:00 p.m. Eastern Time.

KBRA assigns preliminary ratings to five classes of notes issued by Foundation Finance Trust 2026-2 (“FFIN 2026-2”), an asset-backed securitization collateralized by unsecured consumer loans primarily used for home improvements.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below.

AM Best has affirmed the Financial Strength Rating (FSR) of B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb+” (Good) of The Hand-in-Hand Mutual Fire Insurance Company Limited (HIHF) (Guyana). The outlook of the FSR is stable while the outlook of the Long-Term ICR is negative. Concurrently, AM Best has affirmed the FSR of B++ (Good) and the Long-Term ICR of “bbb” (Good) of Hand-in-Hand Mutual Life Assurance Company Limited (HIHL) (Guyana). The outlooks of these Credit Ratings (ratings) are negative. Both entities are collectively referred to as Hand-in-Hand Group.

PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 5:30 pm. Eastern Time from the originally scheduled 5:00 p.m. Eastern Time.

NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced Anthony Palladino as Chief Financial Officer.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function. Results presented at the American Society of Nephrology (ASN) Kidney Week 2026 also showed that, among patients with baseline hematuria (blood in urine), a greater proportion of patients achieved hematuria resolution at Week 37 with sefaxersen versus placebo.

The board of directors of Macy's, Inc. (NYSE: M) today declared a regular quarterly dividend of 19.15 cents per share on Macy's, Inc.’s common stock, payable on January 4, 2027, to shareholders of record at the close of business on December 15, 2026.